Arash Dabestani, Dean of the Arnold & Marie Schwartz College of Pharmacy and Health Sciences co-authored groundbreaking new research published in the Journal of Investigative Dermatology. The study, conducted alongside faculty atYale University, found a substantial portion of topical benzoyl peroxide (BPO) acne and rosacea treatments currently on the market are unstable and contain unacceptably high levels of benzene, a known human carcinogen.
